NO314616B1 - Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes - Google Patents
Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes Download PDFInfo
- Publication number
- NO314616B1 NO314616B1 NO19970567A NO970567A NO314616B1 NO 314616 B1 NO314616 B1 NO 314616B1 NO 19970567 A NO19970567 A NO 19970567A NO 970567 A NO970567 A NO 970567A NO 314616 B1 NO314616 B1 NO 314616B1
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- drug
- ketoconazole
- preparation
- use according
- Prior art date
Links
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 title claims abstract description 25
- 229960004125 ketoconazole Drugs 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims description 18
- 229940079593 drug Drugs 0.000 title claims description 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract description 4
- 239000000126 substance Substances 0.000 title description 4
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 7
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 6
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims abstract description 5
- 230000002498 deadly effect Effects 0.000 claims abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 13
- 206010022489 Insulin Resistance Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010065941 Central obesity Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 2
- 201000008980 hyperinsulinism Diseases 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract description 20
- 229960000890 hydrocortisone Drugs 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 7
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 229960003604 testosterone Drugs 0.000 abstract description 3
- 230000001857 anti-mycotic effect Effects 0.000 abstract 1
- 239000002543 antimycotic Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000008092 positive effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000001610 euglycemic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B1/04—Methods of, or means for, filling the material into the containers or receptacles
- B65B1/08—Methods of, or means for, filling the material into the containers or receptacles by vibratory feeders
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Mechanical Engineering (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/SE1994/000729 WO1996004912A1 (en) | 1994-08-09 | 1994-08-09 | Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes |
Publications (3)
Publication Number | Publication Date |
---|---|
NO970567L NO970567L (no) | 1997-02-07 |
NO970567D0 NO970567D0 (no) | 1997-02-07 |
NO314616B1 true NO314616B1 (no) | 2003-04-22 |
Family
ID=20393155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19970567A NO314616B1 (no) | 1994-08-09 | 1997-02-07 | Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes |
Country Status (14)
Country | Link |
---|---|
US (2) | US5849740A (de) |
EP (2) | EP0779810B8 (de) |
JP (1) | JP3825469B2 (de) |
KR (1) | KR100422162B1 (de) |
AT (1) | ATE244009T1 (de) |
CA (1) | CA2196174C (de) |
CZ (1) | CZ285290B6 (de) |
DE (1) | DE69432905T2 (de) |
DK (1) | DK0779810T3 (de) |
ES (1) | ES2202326T3 (de) |
NO (1) | NO314616B1 (de) |
PT (1) | PT779810E (de) |
SI (1) | SI0779810T1 (de) |
WO (1) | WO1996004912A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69432905T2 (de) * | 1994-08-09 | 2004-05-27 | Cortendo Ab | Verwendung von ketoconazol und verwandten substanzen in medikamenten für die behandlung des typ ii-diabetes |
US6642236B1 (en) * | 1998-12-14 | 2003-11-04 | Cortendo Ab | Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis |
SE9700642D0 (sv) | 1997-02-24 | 1997-02-24 | Kronvall Stefan Med Ab | Medel och sätt för förebyggande och behandling av det metabola syndromet |
GB0001449D0 (en) * | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
GB0118300D0 (en) * | 2001-07-26 | 2001-09-19 | Cortendo Ab | Formulations |
US7081358B2 (en) * | 2001-08-23 | 2006-07-25 | New England Biolabs, Inc. | Method for engineering strand-specific, sequence-specific, DNA-nicking enzymes |
US7094792B2 (en) | 2001-11-22 | 2006-08-22 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
US20040220190A1 (en) * | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
EP1533619B1 (de) | 2003-11-20 | 2009-04-29 | F. Hoffmann-Roche AG | Spezifische Marker für Stoffwechselssyndrome |
US20050215558A1 (en) * | 2004-03-25 | 2005-09-29 | Cincotta Anthony H | Methods of identifying responders to dopamine agonist therapy |
US8137994B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
US8137993B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
ATE528005T1 (de) | 2005-01-10 | 2011-10-15 | Cortendo Ab Publ | 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen |
EP1976526A2 (de) * | 2006-01-10 | 2008-10-08 | Diobex, Inc. | Verfahren und zusammensetzungen zur behandlung von prostatakrebs |
JP2006206605A (ja) * | 2006-03-29 | 2006-08-10 | Metabolic Syndrome I Goeteborg Ab | 代謝性症候群の治療薬 |
EP1886695A1 (de) * | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmazeutische Kombinationen mit einem Aldosteron Synthasehemmer und Glucocorticoid Rezeptorantagonisten oder Cortisol Synthasehemmer oder Corticotropin Releasing Faktor Antagonisten |
BRPI0719835A2 (pt) | 2006-10-02 | 2014-05-06 | Cortendo Invest Ab | Enantiômero de cetoconazol em humanos |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5432176A (en) * | 1988-11-29 | 1995-07-11 | The John Hopkins University | Method of retarding the progression of chronic renal failure |
US5175144A (en) * | 1988-11-29 | 1992-12-29 | The Johns Hopkins University | Method of retarding the progression of chronic renal failure |
DE69432905T2 (de) * | 1994-08-09 | 2004-05-27 | Cortendo Ab | Verwendung von ketoconazol und verwandten substanzen in medikamenten für die behandlung des typ ii-diabetes |
US5591736A (en) * | 1995-07-03 | 1997-01-07 | The Johns Hopkins University | Method of retarding the progression of chronic renal failure |
-
1994
- 1994-08-09 DE DE69432905T patent/DE69432905T2/de not_active Expired - Lifetime
- 1994-08-09 CA CA002196174A patent/CA2196174C/en not_active Expired - Fee Related
- 1994-08-09 ES ES94927881T patent/ES2202326T3/es not_active Expired - Lifetime
- 1994-08-09 WO PCT/SE1994/000729 patent/WO1996004912A1/en active IP Right Grant
- 1994-08-09 SI SI9430454T patent/SI0779810T1/xx unknown
- 1994-08-09 DK DK94927881T patent/DK0779810T3/da active
- 1994-08-09 KR KR1019970700852A patent/KR100422162B1/ko not_active IP Right Cessation
- 1994-08-09 EP EP94927881A patent/EP0779810B8/de not_active Expired - Lifetime
- 1994-08-09 CZ CZ97360A patent/CZ285290B6/cs not_active IP Right Cessation
- 1994-08-09 EP EP03012414A patent/EP1360960A1/de not_active Ceased
- 1994-08-09 JP JP50722396A patent/JP3825469B2/ja not_active Expired - Fee Related
- 1994-08-09 PT PT94927881T patent/PT779810E/pt unknown
- 1994-08-09 US US08/776,983 patent/US5849740A/en not_active Expired - Lifetime
- 1994-08-09 AT AT94927881T patent/ATE244009T1/de active
-
1997
- 1997-02-07 NO NO19970567A patent/NO314616B1/no not_active IP Right Cessation
-
1998
- 1998-12-14 US US09/211,282 patent/US6166017A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
PT779810E (pt) | 2003-11-28 |
DE69432905D1 (de) | 2003-08-07 |
US5849740A (en) | 1998-12-15 |
JPH10510241A (ja) | 1998-10-06 |
DE69432905T2 (de) | 2004-05-27 |
ATE244009T1 (de) | 2003-07-15 |
US6166017A (en) | 2000-12-26 |
KR100422162B1 (ko) | 2004-07-07 |
CA2196174A1 (en) | 1996-02-22 |
ES2202326T3 (es) | 2004-04-01 |
EP0779810B1 (de) | 2003-07-02 |
NO970567L (no) | 1997-02-07 |
AU695011B2 (en) | 1998-08-06 |
EP1360960A1 (de) | 2003-11-12 |
EP0779810B8 (de) | 2003-09-17 |
EP0779810A1 (de) | 1997-06-25 |
NO970567D0 (no) | 1997-02-07 |
WO1996004912A1 (en) | 1996-02-22 |
CZ285290B6 (cs) | 1999-06-16 |
JP3825469B2 (ja) | 2006-09-27 |
SI0779810T1 (en) | 2003-12-31 |
CA2196174C (en) | 2005-03-01 |
KR970704440A (ko) | 1997-09-06 |
CZ36097A3 (en) | 1997-06-11 |
AU7711894A (en) | 1996-03-07 |
DK0779810T3 (da) | 2003-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO314616B1 (no) | Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes | |
RU2198679C2 (ru) | Препараты для лечения метаболического синдрома, содержащие гормон роста человека в комбинации с ингибитором синтеза кортизола | |
TWI250016B (en) | Use of pramipexole for the treatment of addictive disorders | |
US7960410B2 (en) | Method for treating insulin resistance, abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids with a cortisol inhibitor | |
RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
AU2002315814B2 (en) | Medicinal composition for treatment of interstitial cystitis | |
US6423721B1 (en) | Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines | |
US20020032177A1 (en) | Use of D-chiro-inositol in the treatment of conditions associated with hypothalamic gene expression | |
KR20060126586A (ko) | 중증 당뇨병 망막증의 예방제 또는 치료제 | |
WO2021208280A1 (zh) | 五谷虫在制备预防和治疗乳腺增生药物中的应用 | |
US4906649A (en) | Use of a compound for the treatment of sleep disorders and depression | |
KR20100015923A (ko) | 수면관련 호흡 장애를 치료하는 방법들 및 수면관련 호흡 장애 치료용 조성물들 | |
CN114533818A (zh) | 中药组合物在制备防治视网膜色素变性的药物中的应用 | |
WO2004017973A1 (ja) | 統合失調症治療剤 | |
KR100894385B1 (ko) | 녹내장을 치료하기 위한 망막보호제로서의 비여성화에스트로겐의 용도 | |
CN112641765B (zh) | 丙泊酚的抗疲劳制药用途 | |
JP7219476B2 (ja) | 腱滑膜病変を主体とした疾患の治療薬 | |
KR20030097598A (ko) | 코르티솔 길항제를 포함하는 당뇨병 타입 ⅱ의 치료용약제 | |
Shakirah | STH–Secreting Pituitary Adenoma. Acromegaly Case without Successful Result | |
CN115025103A (zh) | 丹参酮iia磺酸钠在制备药物中的应用 | |
CN112138013A (zh) | I化合物在制备治疗糖尿病及相关病症的药中的用途 | |
EP1990053A1 (de) | Pharmazeutische zusammensetzung zur verbesserung der adiponectin-produktion | |
Mamatkulov et al. | Tashkent Pediatric Medical Institute | |
UA45827A (uk) | Спосіб комплексного лікування хворих з гнійно-некротичними ускладненнями синдрому діабетичної стопи | |
JP2006206605A (ja) | 代謝性症候群の治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |